UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

Their core work

University Hospitals of Leicester NHS Trust is one of England's largest acute NHS teaching trusts, running three Leicester hospitals and tightly linked to the University of Leicester. Its core business is frontline patient care, but it also operates major clinical research infrastructure covering cardiology, diabetes, and immune-mediated diseases, and acts as a trial site for European and industry studies. In H2020 it contributed clinical expertise, patients and trial data to health consortia rather than leading science itself. For partners, UHL's value is credible clinical validation, patient recruitment and real-world NHS data.

What they specialise in

How they've shifted over time

Between 2018 and 2019 UHL's H2020 footprint shifted from interventional acute-care trials (EURO SHOCK, focused on ECMO in cardiogenic shock) toward large chronic-disease, data-driven consortia. The newer projects, Hypo-RESOLVE and 3TR, emphasise data harmonisation, single-cell genomics, predictive modelling and disease trajectories across diabetes, autoimmunity, inflammation and allergy. The direction of travel is clear: from running a single randomised trial toward contributing clinical data and patients to precision-medicine platforms.

Expect UHL to keep joining large European precision-medicine and data-harmonisation consortia as a clinical site rather than leading new trials themselves.

How they like to work

UHL joins large pan-European consortia as a clinical research partner, never as coordinator. Across just 3 projects they have accumulated 120 distinct partners in 18 countries — a hub-like footprint driven by the size of Innovative Medicines Initiative-style health consortia. They are a contributor of patients, clinicians and trial infrastructure rather than a scientific lead, which makes them a practical partner for anyone who needs real-world clinical validation.

Despite only 3 H2020 projects, UHL has collaborated with 120 unique partners across 18 countries, reflecting the size of IMI-style health consortia it joins. The reach is pan-European, anchored in UK NHS research infrastructure.

What sets them apart

UHL is one of the UK's largest NHS teaching trusts, giving consortium builders access to a very large multi-ethnic patient base in the East Midlands and the associated specialist clinicians. Unlike a pure academic partner, they bring real-world hospital workflows, routine NHS data and trial delivery capacity in cardiology, diabetes and immunology. Partner with them when a project needs credible clinical validation, patient recruitment or NHS-grade data rather than basic science.

Highlights from their portfolio

• 3TR
  One of the largest IMI2 precision-medicine consortia, spanning autoimmunity, inflammation and allergy with single-cell genomics and predictive modelling through 2026.
• Hypo-RESOLVE
  Flagship European effort to redefine hypoglycaemia outcomes in diabetes using harmonised trial data, CGM and patient-reported outcomes.
• EURO SHOCK
  Randomised trial testing ECMO-based strategies in cardiogenic shock — a rare interventional cardiology H2020 project.